EEST Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission ...

Androgen deprivation therapy is a lifesaving therapy used by thousands of men each year, but some patients are warning of ...

The European Commission has granted marketing authorization in the European Union (EU) for German pharma major Bayer’s Nubeqa ...

EEST Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission granted approval ...

During a live event, Jahan Aghalar, MD, discussed the efficacy and safety of darolutamide plus ADT in mHSPC in the ARANOTE ...

Berlin: Bayer has received marketing authorization from the European Commission in the European Union (EU) for Nubeqa ...

Hormone therapy for metastatic prostate cancer comes in three main types: ADT, androgen synthesis inhibitors, and androgen receptor blockers.

In patients with biochemical recurrence after prostate cancer surgery, the optimal duration of hormone therapy after salvage radiation therapy has been debated.

European Union approves Bayer’s Nubeq for patients with advanced prostate cancer: Berlin Tuesday, July 22, 2025, 11:00 Hrs [IST] The European Commission has granted marketing au ...

With regard to the choice of bone-protecting agent, denosumab (Xgeva) improved bone density and reduced fracture risk in a placebo-controlled trial involving men with non-metastatic HSPC. Denosumab ...